These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38345708)

  • 21. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
    Yanagisawa T; Mori K; Kawada T; Katayama S; Uchimoto T; Tsujino T; Nishimura K; Adachi T; Toyoda S; Nukaya T; Fukuokaya W; Urabe F; Murakami M; Yamanoi T; Bekku K; Komura K; Takahara K; Hashimoto T; Fujita K; Azuma H; Ohno Y; Shiroki R; Uemura H; Araki M; Kimura T;
    Urol Oncol; 2024 Nov; 42(11):374.e21-374.e29. PubMed ID: 39085019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
    Massari F; Mollica V; Fiala O; De Giorgi U; Kucharz J; Vitale MG; Molina-Cerrillo J; Facchini G; Seront E; Lenci E; Bourlon MT; Carrozza F; Pichler R; Lolli C; Myint ZW; Kanesvaran R; Torniai M; Rescigno P; Gomez de Liaño A; Zakopoulou R; Buti S; Porta C; Grande E; Santoni M
    Eur Urol Oncol; 2024 Oct; 7(5):1123-1131. PubMed ID: 38575409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
    Chablani PV; Karrison T; Stadler WM
    Clin Genitourin Cancer; 2022 Dec; 20(6):510-514. PubMed ID: 35869002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world data on IO-based therapy for metastatic renal cell carcinoma.
    Stühler V; Herrmann L; Rausch S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3249-3258. PubMed ID: 35907009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
    Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
    Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
    Target Oncol; 2024 Jul; 19(4):587-599. PubMed ID: 38704759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.
    Ishihara H; Nishimura K; Ikeda T; Fukuda H; Yoshida K; Iizuka J; Kondo T; Takagi T
    Urol Oncol; 2024 Sep; 42(9):291.e27-291.e37. PubMed ID: 38653590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
    Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
    Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.
    Yoshida K; Nagasaka N; Kondo T; Kobari Y; Ishihara H; Fukuda H; Iizuka J; Ishida H; Takagi T
    Int J Clin Oncol; 2024 Oct; 29(10):1538-1547. PubMed ID: 39110357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
    Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
    Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nakai Y; Nakayama M; Nonomura N; Uemura M
    Anticancer Res; 2021 Nov; 41(11):5811-5816. PubMed ID: 34732455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
    Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
    Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Chen YW; Rini BI
    Curr Oncol Rep; 2022 Jun; 24(6):695-702. PubMed ID: 35247142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
    Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
    Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
    Nathan P; Venugopal B; Ali J; Allison J; Ceruso M; Charnley N; Griffiths R; Michael A; Moore K; Perrot V; Prendergast Á; Sharma A; Szabados B; Larkin J
    Clin Genitourin Cancer; 2024 Oct; 22(5):102141. PubMed ID: 39107157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.